S
ARS Pharmaceuticals, Inc.
SPRY · NASDAQ · Healthcare · 561M
Closing price
$4.23
-7.24% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
3.6×
Enterprise value / EBITDAEV/EBITDA
-2.8×
Free cash flow yieldFCF yield
-41.1%
Return on equityROE
-149.9%
Operating margin
-212.9%
Net debt / EBITDAbalance-sheet strength
-0.3×
Interest coverage
-69.0×
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.